genOway allows Addgene to distribute its FLEX technology

genOway grants Addgene a non-exclusive sub-license for the distribution of plasmids containing the FLEX technology to academic researchers

Lyon, France – June 20, 2018 - genOway (ALTERNEXT-NYSE EURONEXT: ALGEN; ISIN: FR0004053510), the biotechnology company dedicated to the development of genetically modified mouse, rat and cell models, announced today that it has partnered with Addgene to help disseminate its FLEX technology to academic researchers.

FLEX technology allows scientists to induce expression of a gene of interest or a reporter gene at an appropriate time and in a specific tissue. With this agreement, Addgene can now provide the academic community with plasmids containing FLEX technology. A number of these FLEX plasmids will also be available in packaged adeno-associated virus (AAV) format via Addgene.

Academic researchers around the globe share their plasmids through Addgene thus enabling others to complete their experiments more quickly and accelerating discovery. Plasmids with FLEX technology are important components of both basic and applied biological research projects. Through this agreement, genOway’s FLEX technology will continue to help researchers expand their understanding of diverse topics, including brain function and cellular physiology.

For-profit organizations interested in obtaining and using FLEX technology should contact genOway directly for a commercial license.

FLEX technology is covered by US patent no. 7,074,611 and EP patent no. 1,383,891, whose inventors are Prof. Pierre Chambon, Dr. Frank Schnütgen and Dr. Norbert Ghyselinck at the Institut de Génétique et de Biologie Moléculaire et Cellulaire (France).

Alexandre Fraichard, general manager and founder of genOway, declared: “We are proud to provide the world’s largest repository of biological materials with this license and thus support the access of academic researchers to the most advanced research tools.”

“FLEX technology has enabled scientists to gain insights into a variety of biological phenomena and Addgene is excited to have genOway’s support so that plasmids containing this technology can continue accelerating discovery,” said Joanne Kamens, PhD, Executive Director of Addgene.


About genOway

genOway (ALTERNEXT-NYSE: ALGEN) is a biotechnology company developing genetically modified and high value-added research models for the bio-pharmaceutical, chemical, agrochemical and food industries as well as academic research. With highly qualified scientific personnel, the company has a workforce of 95 people and operates in 28 countries in Europe, Asia and North America, supplying more than 275 customers. It is a market leader in terms of both size and customer portfolios. The company’s development is founded upon both a broad and exclusive technology platform as well as strong intellectual property rights combining patents and licensing agreements. Taking advantage of the global trend toward outsourcing the production of genetically modified research models, genOway has signed contracts with leaders of the pharmaceutical industry (Janssen R&D, GSK, Pfizer, etc.) and with prestigious academic research centers including the UK’s King’s College and University of Manchester; Harvard, Caltech and the National Institutes of Health in the US; the Institut Pasteur in France; and NGFN and the Max Planck Institutes in Germany. For more information, visit our website


Warning: This press release expressly contains, in an implicit manner, certain prospective statements concerning genOway and its activity. These statements rely on certain risks, known or unknown, uncertainty or other factors that may lead to actual results, financial conditions, performance or achievements on the part of genOway that may differ significantly from the results, financial conditions, performance or achievements expressed or implied in these prospective statements. genOway is issuing this press release on the present date and is not committed to update the prospective statements contained therein, either as a result of new information, future events or other. For a description of the risks or uncertainty of a nature to cause a difference between genOway’s actual results, financial conditions, performance or achievements and those contained in the prospective statements, please refer to the section on “Risk Factors” in the prospectus available on the genOway website:


Download Press Release as PDF